No­var­tis of­fers glimpse at BTK in­hibitor plans be­yond lead in­di­ca­tions: #AAD24

No­var­tis pro­vid­ed a peek Sat­ur­day of how it might ex­pand de­vel­op­ment of its ex­per­i­men­tal drug remi­bru­ti­nib, a BTK in­hibitor be­ing test­ed in a range of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.